Protecting First Responders January 9, 2016 • admin • Keeping our heroes safe from the dangers of chemical exposures. Related News Countervail Corporation Awarded Additional $343,000 SBIR Phase II Grant for Continued Development of Medical Countermeasure to Nerve Agents September 9, 2013 Countervail receives additional $630,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. August 3, 2015
